Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00902304
Registration number
NCT00902304
Ethics application status
Date submitted
28/04/2009
Date registered
15/05/2009
Date last updated
4/12/2012
Titles & IDs
Public title
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
Query!
Scientific title
A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy
Query!
Secondary ID [1]
0
0
CVAL489AAU01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
VIPER-BP
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypertension
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
Treatment: Drugs - Valsartan and amlodipine
Treatment: Drugs - Usual care
Treatment: Drugs - Valsartan
Treatment: Drugs - Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Active Comparator: Usual care - Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
Experimental: Monotherapy (initial monotherapy arm) - Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
Experimental: Combination (initial combination therapy arm) - Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
Treatment: Drugs: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
Treatment: Drugs: Valsartan and amlodipine
From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
Treatment: Drugs: Usual care
As directed by investigator
Treatment: Drugs: Valsartan
Valsartan 160mg per day to 320mg per day orally
Treatment: Drugs: Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target
Query!
Assessment method [1]
0
0
BP target groups were: <= 125/75mmHg, <= 130/80mmHg and <= 140/90mmHg. The BP target was based on the patient's clinical risk profile as specified by National Heart Foundation of Australia guidelines.
Query!
Timepoint [1]
0
0
26 weeks
Query!
Secondary outcome [1]
0
0
Change in Mean Sitting Systolic Blood Pressure
Query!
Assessment method [1]
0
0
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
Query!
Timepoint [1]
0
0
Baseline and 26 weeks
Query!
Secondary outcome [2]
0
0
Change in Mean Sitting Diastolic Blood Pressure
Query!
Assessment method [2]
0
0
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
Query!
Timepoint [2]
0
0
Baseline and 26 weeks
Query!
Secondary outcome [3]
0
0
Change in Absolute Cardiovascular Risk Score
Query!
Assessment method [3]
0
0
The absolute cardiovascular risk assessment uses the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years. A score of <10% is a low risk, 10 to 15% is a moderate risk, and >15% is a high risk.
A decrease indicates improvement.
Query!
Timepoint [3]
0
0
Baseline and 26 weeks
Query!
Secondary outcome [4]
0
0
Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy
Query!
Assessment method [4]
0
0
The rate of all adverse events by preferred terms as determined by the General Practice investigators to be related to study intervention therapy was reported. Percentage of adverse events was calculated based on the number of participants analyzed. 41 adverse events were not reported as inadequate information was supplied to allow determination of drug treatment at onset.
Query!
Timepoint [4]
0
0
26 weeks
Query!
Secondary outcome [5]
0
0
Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments
Query!
Assessment method [5]
0
0
A comparison of the early responders was made based on the blood pressure measurements taken at the week 6 visit window according to gender and guideline targets. The guideline targets were: patients with renal impairment: 125/75 mmHg; patients with end-organ damage/cardiovascular disease: 130/80 mmHg; others: 140/90 mmHg.
Query!
Timepoint [5]
0
0
26 weeks
Query!
Secondary outcome [6]
0
0
Change in the EQ-5D Score
Query!
Assessment method [6]
0
0
The EQ-5D total indexed score (AUS) measures self-reported quality of life with the following 5 dimensions: mobility (range 1,2,3), self-care (range 1,2,3), usual activity (range 1,2,3), pain/discomfort (range 1,2,3) and anxiety/depression (range 1,2,3), where a 1 indicates no problems, a 2 indicates moderate problems, and a 3 indicates severe problems. The range of possible utility scores are between -0.217 (derived from worse responses from all 5 dimensions with severe problems ie 3,3,3,3,3) and 1.000 (no problems for all 5 dimensions) for each dimension. An increase in EQ-5D indexed score (AUS) indicates improvement.
Query!
Timepoint [6]
0
0
Baseline and 26 weeks
Query!
Secondary outcome [7]
0
0
Number of Patients With Depression
Query!
Assessment method [7]
0
0
Patients with depression refers to potential depressive symptoms, not clinically diagnosed depression. The 2 question Arrol screening tool was used to determine if the patient had potential depressive symptoms. The 2 questions are: During the last month have you often been bothered by feeling down, depressed or hopeless? During the past month have you often been bothered by little interest or pleasure in doing things? The presence of potential depressive symptoms was determined by a 'yes' answer to either of these questions.
Query!
Timepoint [7]
0
0
Baseline and week 26
Query!
Secondary outcome [8]
0
0
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26
Query!
Assessment method [8]
0
0
The CES-D score was from 0 to 30, with a higher score indicating a higher level of depression.
The categories for the score are: 0 to 9 suggests no depression; 10 to 15 suggests mild depression; 16 to 24 suggests moderate depression; 24 or above suggests severe depression.
Query!
Timepoint [8]
0
0
Baseline and week 26
Query!
Secondary outcome [9]
0
0
Participants With End Organ Disease at Baseline and Week 26
Query!
Assessment method [9]
0
0
A patient was considered to have end organ damage with either of the following: 1) proteinuria (dipstick = 1+ or more or protein/creatinine ratio > 30mg/mol or 24h urine protein > 0.3g); 2) no proteinuria, but presence of microalbuminuria (urine albumin/creatinine ratio 3.6 to 25mg/mol(male) or 3.6 to 35mg/mol (female) detected; 3) no proteinuria or microalbuminuria, but presence of macroalbuminuria (urine albumin/creatinine ratio > 25mg/mol(male) or >35mg/mol (female) detected OR 4) ECG evidence of LVH (Sokolow-Lyon voltage criteria values >= 38mm).
Baseline potential for end organ damage was calculated in all 1562 randomised patients based on the criteria outlined above. If no investigation/data available, assumed no end-organ damage.
It is important to note that given the limited number of ECGs at 26 weeks, between group comparisons should be limited to the two time points (baseline and 26 weeks).
Query!
Timepoint [9]
0
0
Baseline and week 26
Query!
Secondary outcome [10]
0
0
Change in Self-care Behavior Score From Baseline to Week 26
Query!
Assessment method [10]
0
0
A modified self-care behavior tool (questionnaire) was used to calculate 2 domain scales: maintenance and confidence. Each domain has a standardized score between 0 and 100. Self-care is best represented by maintenance. Confidence is an important process that moderates the relationship between self-care and outcomes. Higher index score suggests better self-care. A score of 70 or greater can be used as the cut-point to judge self-care adequacy.
Query!
Timepoint [10]
0
0
Baseline and week 26
Query!
Secondary outcome [11]
0
0
Rate of Treatment Compliance
Query!
Assessment method [11]
0
0
The rate of compliance was planned to be estimated from the quantity of unused medication returned at each scheduled visit over the entire follow-up period. Rate of compliance = (tablets supplied - tablets returned)/(tablets for 100% compliance).
Query!
Timepoint [11]
0
0
26 weeks
Query!
Secondary outcome [12]
0
0
Number of Patients With Major Clinical Endpoints
Query!
Assessment method [12]
0
0
Major clinical endpoints measured were all-cause mortality and fatal and non-fatal cardiovascular events (e.g. acute myocardial infarction, stroke and heart failure).
Query!
Timepoint [12]
0
0
26 weeks
Query!
Eligibility
Key inclusion criteria
- newly diagnosed or currently treated hypertensive patients who have not attained their
blood pressure target and require active pharmacological treatment as recommended by
the local guidelines as judged by the general practitioner
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- significantly elevated blood pressure (severe hypertension)
- requiring 3 or more antihypertensive drugs
- severe kidney disease or dialyses
- clinical diagnosis requiring concomitant therapy with antihypertensive treatment that
would be outside the therapies allowed under study protocol
Other protocol-defined inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2337
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Professor Garry Jennings-Co Principal Investigator - Melbourne
Query!
Recruitment hospital [2]
0
0
Professor Simon Stewart-Principal Investigator - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New Jersey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Baker Heart and Diabetes Institute
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the efficacy of an intensive blood pressure management strategy
compared to usual care in a primary care (general practice) setting.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00902304
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00902304
Download to PDF